• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Abbott Laboratories

Abbott Laboratories

Abbott Laboratories ABT

Last Price$38.55Day Change (%)-0.77%
Open Price$38.80Day Change ($)-0.30
Day Range38.21–38.8352-Week Range36.00–51.74

As of Tue 5/3/2016 6:45:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Robbins Arroyo LLP: Acquisition of St. Jude Medical, Inc. (STJ) by Abbott Laboratories (ABT ) May Not Be in Shareholders' Best Interests

    Robbins Arroyo LLP: Acquisition of St. Jude Medical, Inc. (STJ) by Abbott Laboratories ( ABT ) May Not Be in Shareholders' Best Interests

  2. New Avon Appoints Abbott Labs Executive as New CEO

    New Avon Appoints Abbott Labs Executive as New CEO

  3. Top 10 Buys and Sells by the Ultimate Stock-Pickers

    A group of top managers continue to keep looking for good investment opportunities, while taking full advantage of a rising (and potentially overvalued) market to book some gains.

  4. Diversifying in a Shrinking World

    Simple formulas for foreign exposure lose luster.

  5. Alere Says It Rejected Abbott Offer to Terminate Merger Deal

    Alere Says It Rejected Abbott Offer to Terminate Merger Deal

  6. Alere Says It Rejected Abbott Offer to End Their Merger Deal

    Alere Says It Rejected Abbott Offer to End Their Merger Deal

  7. Robbins Arroyo LLP: Alere, Inc. (ALR) Misled Shareholders According to a Recently Filed Class Action

    Robbins Arroyo LLP: Alere, Inc. (ALR) Misled Shareholders According to a Recently Filed Class Action

  8. Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Alere Inc. (NYSE: ALR) Securities Case

    Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Alere Inc. (NYSE: ALR) Securities Case

  9. Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors

    Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors

  10. argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target

    argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.